An internal cysteine protease domain (CPD) autoproteolytically regulates Clostridium difficile glucosylating toxins by releasing a cytotoxic effector domain into target cells. CPD activity is itself allosterically regulated by the eukaryote-specific molecule inositol hexakisphosphate (InsP 6 ). Although allostery controls the function of most proteins, the molecular details underlying this regulatory mechanism are often difficult to characterize. Here we use chemical probes to show that apo-CPD is in dynamic equilibrium between active and inactive states. InsP 6 markedly shifts this equilibrium toward an active conformer that is further restrained upon binding a suicide substrate. Structural analyses combined with systematic mutational and disulfide bond engineering studies show that residues within a b-hairpin region functionally couple the InsP 6 -binding site to the active site. Collectively, our results identify an allosteric circuit that allows bacterial virulence factors to sense and respond to the eukaryotic environment.
a r t i c l e s
Allostery is central to the regulation of many cellular processes. This ubiquitous mechanism refers to the control of protein behavior at a distance, with a change at one site (the allosteric site) affecting the function at a second. The functional coupling between these two sites is often mediated through structural rearrangements 1 . A wellcharacterized example is the cooperative binding of oxygen to hemoglobin, whereby ligand binding at the allosteric site alters protein function through changes in quaternary structure (reviewed in refs. [2] [3] [4] . Although conformational changes induced by allosteric effectors can frequently be detected, understanding how these structural alterations translate into changes in function is typically more challenging. This is because defining an allosteric signaling pathway requires the identification of specific amino acids that couple changes in structure or dynamics to changes in function.
The regulation of the C. difficile glucosylating toxin CPD by the small molecule InsP 6 is a useful system for studying allosteric signaling pathways [5] [6] [7] [8] . Clostridium difficile CPDs belong to a conserved family of autocatalytic proteases within bacterial toxins that are allosterically activated by InsP 6 , a metabolite abundant in the eukaryotic cytosol 6, 9 . These clan CD protease members cleave exclusively on the C-terminal side of a leucine residue to liberate toxin effectors from receptor-binding domains and other effectors 7, [10] [11] [12] [13] . InsP 6 activates bacterial CPDs by binding to a basic cleft that is distinct from the active site. This binding event induces conformational changes that are presumably linked to protease activation 11, 14, 15 . More specifically, InsP 6 has been proposed to induce rearrangement of a β-hairpin structure to permit formation of the substrate-binding pocket and alignment of the catalytic residues 11, 14, 15 .
Clostridium difficile CPDs autocatalytically cleave the glucosylating toxins TcdA and TcdB at a single site to liberate a cytotoxic effector domain into target cells 12, 16 . This event occurs at the later stages of a multistep intoxication process 17, 18 . Glucosylating toxins first enter cells using receptor-mediated endocytosis; during acidification of the endosome, they undergo a conformational change that mediates toxin translocation across the endosomal membrane. Exposure of the CPD to InsP 6 in target cells activates the protease, leading to autocatalytic cleavage. This autoprocessing event releases the glucosyltransferase domain from the endosome into the cytosol and presumably enhances glucosyltransferase binding to its Rho GTPase substrates at the plasma membrane 19 . Glucosylation of Rho GTPases inhibits their function, leading to cell rounding and ultimately cell death 17 .
Notably, the glucosylating toxins of C. difficile are the primary virulence factors of this important and emergent nosocomial pathogen [20] [21] [22] [23] . Because C. difficile is naturally antibiotic resistant, there is great interest in developing therapeutics that target glucosylating toxin function 20, 21, 24 . A more thorough understanding of CPDmediated regulation of these toxins could facilitate the design of such therapeutics, because CPD activity is necessary for optimal toxin function 7, 10 . Understanding how the eukaryotic-specific small molecule InsP 6 activates the CPD would further provide mechanistic insight into how allostery integrates environmental signals to regulate protein function.
In this study, we examined the mechanism underlying the allosteric activation of C. difficile TcdB CPDs by InsP 6 . Using a combination of structural analyses and an activity-based probe specific for TcdB CPD, we show that, even without InsP 6 , TcdB CPD transiently samples the activated conformation. InsP 6 binding shifts the conformational equilibrium of the enzyme to an active conformer that is further stabilized by reaction with a suicide substrate. Using mutational studies, we demonstrate that adoption of this activated conformation depends on an interconnected network of residues that functionally couple InsP 6 binding to protease activation. These results therefore provide detailed mechanistic insight into a tightly controlled allosteric regulatory system used by a large family of bacterial pathogens. This information may facilitate the discovery of allosteric circuits in other systems and could aid in the development of therapeutic agents that disrupt such networks.
RESULTS

Measuring TcdB activation with an activity-based probe
To dynamically monitor the InsP 6 -induced activation of C. difficile TcdB CPD, we sought to develop a reliable assay. Although autoprocessing can be used as a measure of InsP 6 -induced activation of TcdB CPD (Supplementary Fig. 1 ), this assay lacks the sensitivity needed to accurately measure the kinetics of this process. Fluorogenic substrate assays for the CPD also lack sensitivity because high substrate concentrations are needed to generate detectable activity 14 . In contrast, activity-based probe (ABP) labeling can be used to sensitively detect InsP 6 -induced CPD activation 25 (Fig. 1a) . ABPs are small molecules that exclusively label active enzyme 26, 27 . ABPs contain an electrophilic group that can react with the active site nucleophile of an enzyme only when the protein has assumed a catalytically competent conformation . We previously developed an ABP, AWP19, that specifically labels the CPD of full-length TcdB 25 . This probe consists of (i) an acyloxymethyl ketone (AOMK) reactive group that covalently modifies the catalytic cysteine of clan CD proteases [28] [29] [30] , (ii) a Ser-Leu peptide sequence that directs inhibitor binding to the CPD 24 and (iii) a Cy5 fluorophore tag that permits detection of the labeled enzyme. The Ser-Leu specificity element of AWP19 was identified by screening a small positional scanning library of inhibitors against TcdB CPD 25 .
Titration of InsP 6 against TcdB CPD with excess AWP19 led to dose-dependent labeling of the protease in a manner dependent on the catalytic cysteine (Fig. 1b) . This analysis yielded an activation constant (EC 50 ) for TcdB CPD of 0.17 ± 0.06 µM (Fig. 1c) , the concentration of InsP 6 at which probe labeling is half maximal. Notably, this value is identical to the EC 50 we determined using the standard autocleavage assay (Supplementary Fig. 1) , validating AWP19 as a tool for measuring CPD activation.
Because AWP19 covalently labels the target only when the active site forms, it can be used to monitor the activation state of the CPD. We exploited this property to determine whether TcdB CPD could achieve an activated conformation independent of InsP 6 . Probe labeling with AWP19 indicated that ~10% of apo-CPD could be labeled in the absence of InsP 6 , whereas the catalytic cysteine mutant was not labeled at all (Fig. 1b) . Furthermore, incubation of apo-CPD with probe for an extended period of time led to a time-dependent increase in labeling, with ~70% of the apoenzyme being labeled after 16 h (Fig. 2a) . Likewise, preincubation of apo-CPD with an unlabeled CPD-specific inhibitor (Ac-GSL-AOMK 25 ) was sufficient to block probe labeling of the CPD in a time-dependent manner (Fig. 2b) , with ~70% of apo-CPD modified by the inhibitor after 16 h of treatment. The observed probe labeling of apo-CPD was not due to contamination with InsP 6 during CPD purification from Escherichia coli grown in InsP 6 -containing LB medium, because apo labeling was also observed when the CPD was purified from E. coli grown in minimal medium (data not shown). These results demonstrate that apoTcdB CPD can transiently sample the activated conformation .
We next used the probe to measure the effect of InsP 6 binding on activation of the CPD. Whereas TcdB CPD labeling without InsP 6 occurred very slowly (0.91 arbitrary units (AU) min −1 , Fig. 2c , inset), InsP 6 markedly increased the rate of labeling in a dose-dependent manner (142 AU min −1 at 1 µM InsP 6 , Fig. 2 ). Furthermore, we observed that ~20% of the TcdB 1-804 autocleavage substrate undergoes CPD-dependent autoprocessing when it is produced in the InsP 6 -free environment of E. coli (Supplementary Fig. 2 ). These observations indicate that the TcdB CPD containing an N-terminal extension can also adopt the 'on' state during expression in E. coli. Notably, this transient sampling of the on state by the apoenzyme was specific to TcdB CPD, because expression of the related Vibrio cholerae MARTX (MARTX Vc ) CPD in E. coli did not lead to autoprocessing 14, 31, 32 , and V. cholerae CPD did not react with AWP19 without InsP 6 (Supplementary Fig. 3 ). Together these results support the conclusion that apoTcdB CPD can adopt an activated conformer without InsP 6 and that InsP 6 binding directly enhances the reactivity of the catalytic cysteine by shifting the conformational equilibria of TcdB CPD to an activated form.
Small molecule binding and CPD conformational mobility
For the AWP19 probe to label TcdB CPD, the protease must productively bind the peptide as it would a protein substrate 13, 25 . In related clan CD proteases, this inhibitor-binding event 'locks' these enzymes in an active conformation 33, 34 . We questioned whether binding of a covalent inhibitor in the CPD active site might similarly induce retention of the enzyme in an active confirmation. Therefore we examined a r t i c l e s the effect of inhibitor modification on the conformational dynamics of TcdB CPD. To determine whether the peptide backbone of the probe was required to constrain the CPD in the active form, we compared the effect of modifying TcdB CPD with the AOMK probe relative to the general alkylating agent N-ethylmaleimide (NEM). We used limited proteolysis as a readout for conformational mobility, because this assay has been used to demonstrate that InsP 6 stabilizes a proteaseresistant conformation of C. difficile CPDs 5,15 ( Fig. 3a, untreated) . Covalent modification of apoTcdB CPD by either inhibitor did not affect the limited proteolysis profile relative to untreated enzyme ( Fig. 3a , (−) panel), indicating that covalent modification alone is not sufficient to protect the enzyme from protease degradation.
However, when InsP 6 was added to these variants, AOMK-treated but not NEM-modified CPD showed increased protection from protease degradation (Fig. 3a , (+) panel). Covalent modification of TcdB CPD by either NEM or AOMK inhibitor blocked AWP19 labeling of these variants, indicating that the catalytic cysteine of both variants were modified to similar extents ( Supplementary Fig. 4 ). These results suggest that inhibitor modification in the context of substrate recognition is necessary to shift the equilibrium to a more stable conformer upon InsP 6 addition. Because the TcdB CPD used in these analyses had been covalently modified in its apo form, we tested the effect of covalently modifying TcdB CPD in the presence of InsP 6 . Therefore we covalently modified 
a r t i c l e s
TcdB CPD with either peptide AOMK or NEM in the presence of InsP 6 , repurified the enzyme after these treatments and subjected the TcdB CPD variants to complete trypsin digestion. As we expected, only AOMK modification of the CPD, and not NEM modification, markedly stabilized the enzyme (Fig. 3b) . Notably, InsP 6 treatment increased the stability of the CPD even after repurification of the enzyme, suggesting that InsP 6 remains associated with TcdB CPD during this procedure (Fig. 3b) . These findings indicate that, although InsP 6 binding to TcdB CPD can restrict its conformational dynamics, substrate binding by the protease further constrains the protease in the active form. Another measure of TcdB CPD conformational mobility is its ability to release InsP 6 after the repurification procedure. We therefore created an assay that measures the activation of MARTX Vc CPD as a result of transfer of InsP 6 from TcdB CPD. Whereas we observed no activation of the MARTX Vc CPD after addition of apoTcdB CPD, addition of either InsP 6 -treated TcdB CPD or NEM-bound, InsP 6 -treated TcdB CPD markedly increased its activity (Fig. 3c) . In contrast, addition of InsP 6 -treated TcdB CPD covalently modified by the AOMK peptide inhibitor led to only a minimal increase in MARTX Vc CPD activity. Complete trypsin digestion of all InsP 6 -treated TcdB CPD variants, including NEM-bound and AOMK-bound variants, confirmed that similar levels of InsP 6 were bound to each (Fig. 3c) . Together, these results suggest that substrate recognition by an InsP 6 -bound TcdB CPD restrains its conformational mobility such that it cannot release InsP 6 without complete degradation of the protein. Thus, substrate recognition by TcdB CPD, in the context of binding to InsP 6 , would seem to 'rigidify' the enzyme.
Effect of substrate binding on TcdB CPD structure
To gain insight into the effect of substrate binding on TcdB CPD conformation in the presence of InsP 6 , we solved the crystal structure of InsP 6 -bound TcdB CPD (Fig. 4a and Table 1 ) and compared it to that of the AOMK-modified, InsP 6 -bound TcdB CPD 25 . The structure of TcdB CPD is highly similar to the recently reported structure of its close homolog (56% identity) TcdA CPD 15 (r.m.s. deviation, 1.3 Å).
Indeed, most of the sequence differences between the two CPDs are outside of regions involved in InsP 6 binding and catalytic activity. The active site residues are completely conserved (Fig. 4b) , and residues in the InsP 6 -binding site are also conserved with the minor exception of two conservative basic substitutions (Lys577→Arg575, Lys754→Arg752; Fig. 4c ). Core residues essential to the structure of the β-flap are also well conserved, including the π-cation interaction of Arg745 and Trp761 as well as Leu755, Glu753 and Asn747 (discussed below). Although the TcdA and TcdB CPDs are moderately divergent at the sequence level, their structural elements necessary for InsP 6 binding and P1 leucine selectivity are tightly conserved .
Comparison of the InsP 6 -bound TcdB CPD structure with that of InsP 6 -bound TcdB covalently modified by an Ac-GSL-AOMK peptide in the active site (PDB 3PA8; ref. 25) shows that the two structures are essentially superimposable (r.m.s. deviation, 0.6 Å; a r t i c l e s Supplementary Fig. 5 ). This observation implies that the active site forms upon InsP 6 binding and furthermore that substrate binding does not make an induced fit. This is consistent with the observation that inhibitor binding does not alter the structure of InsP 6 -bound MARTX Vc CPD 13 . These results suggest that the allosteric activation mechanism induced by InsP 6 binding organizes the active site so that it can directly bind substrate.
Tryptophan fluorescence identifies an allosteric circuit
As in the structures of bacterial CPDs, InsP 6 binds to a positively charged cleft that is distal from the active site, and an antiparallel β-hairpin structure (termed the β-flap) appears to bridge the InsP 6 and substrate-binding pockets 11, [13] [14] [15] . This β-flap structure has been proposed to form upon InsP 6 binding to the protease 6, 8 , because residues on one side of the β-flap interact with InsP 6 , and residues on the other side form the substrate-binding pocket (Fig. 4) . In MARTX Vc CPD, residues within this region respond to InsP 6 binding 11 . Nevertheless, without an apo structure, the precise conformational changes that occur upon InsP 6 binding remain unknown.
To test whether InsP 6 -induced conformational rearrangements in the β-flap region could be detected in TcdB CPD, we developed an assay that monitors the mobility of a conserved β-flap tryptophan found in all bacterial CPDs 6, 8 . This β-flap tryptophan helps stabilize the substratebinding pocket of bacterial CPDs and affects the responsiveness of the enzyme to InsP 6 (refs. 11,14,15) . Because the intrinsic fluorescence of tryptophan is strongly affected by its immediate environment 35 , we assessed whether InsP 6 binding induces changes in the intrinsic fluorescence of β-flap Trp761. Conveniently, Trp761 is the sole tryptophan in TcdB CPD; thus, all changes in tryptophan fluorescence emission can be attributed to changes in the local environment around this residue. Addition of InsP 6 to TcdB CPD led to a dose-dependent increase in tryptophan fluorescence and concomitant decrease in the maximum wavelength of emission (Fig. 5a) , consistent with InsP 6 binding to the CPD causing Trp761 to enter a more hydrophobic environment 35 . Thus, tryptophan fluorescence can be used to sensitively probe structural changes induced by InsP 6 in the β-flap region.
In the InsP 6 -bound structures of TcdA 15 and TcdB CPD (Fig. 4 ), Trp761 appears to be stabilized by a network of interactions that extends from the β-flap down to the InsP 6 -binding site. Trp761 forms a π-cation interaction with Arg745, whereas Arg745 is itself stabilized by an electrostatic interaction with Glu753. This latter residue also forms a hydrogen bond with Asn747 which, in turn, hydrogen-bonds with the main chain amide of the InsP 6 -interacting residue Arg751 (Fig. 6) . To determine the functional importance of these interactions on the InsP 6 -induced movement of Trp761, we examined the effect of mutating residues in the β-flap region on tryptophan fluorescence and CPD activity. Conservative mutation of Arg745 severely decreased tryptophan fluorescence but only slightly affected CPD activity (reducing it by a factor of 3), whereas a stronger mutation (R745Q) completely abrogated tryptophan fluorescence and diminished CPD function by a factor of 25 (Fig. 5b,c) . Disruption of the salt bridge between Arg745 and Glu753 by an E753Q mutation led to slight decreases in tryptophan fluorescence shift and CPD activity (Fig. 5b,c) , whereas a more severe mutation, E753N, abrogated the tryptophan fluorescence change altogether and reduced protease function by a factor of 20. The N747A mutation similarly reduced the tryptophan fluorescence shift and decreased CPD activity by a factor of 24. Taken together, the results demonstrate that InsP 6 -induced changes in tryptophan fluorescence depend on a network of interactions between β-flap residues and that changes in tryptophan fluorescence directly correlate with levels of protease activity.
We observed similar effects on tryptophan fluorescence and protease activity upon mutation of residues that interact with InsP 6 . Disruption of the electrostatic interactions between these residues and EC 50 activity are purple sticks. EC 50 values for different point mutants were measured using the probe labeling assay and are mean ± s. (Fig. 5b,d) , even though Trp761 is far removed from these InsP 6 -binding residues. Our finding that tryptophan fluorescence shifts become saturated even at high InsP 6 concentrations suggests that the range of InsP 6 -induced movement of Trp761 is diminished in the InsP 6 -binding site mutants relative to wild type. Thus, InsP 6 -induced movement of Trp761 seems to depend on a network of interactions extending from the InsP 6 -binding site through the β-flap region.
A possible mechanism for allosteric signaling to the active site involves a network of interactions that have a specific spatial and temporal order 2 . To explore this possibility, we disrupted the interconnectedness of this network by carrying out a salt-bridge swap. Residues in the Arg745-Glu753 salt bridge were exchanged to form the R745E E753R double mutant. Although this mutant retains the critical β-flap salt bridge, it loses the π-cation interaction between Arg745 and Trp761 and the hydrogen bond between Asn747 and Glu753. Accordingly, the activity of the double mutant was decreased by a factor of 23 relative to wild-type TcdB CPD (Fig. 4c) . Collectively, these results identify a conduit of interconnected residues that communicate InsP 6 binding to the active site.
Disulfide bond engineering the b-flap region
If InsP 6 binding directly induces formation of the β-flap, engineering a stabilization of this structure should improve the responsiveness of the CPD to InsP 6 . To this end, we introduced disulfide bonds designed to stabilize the β-flap structure and examined their effect on protease activity in response to InsP 6 (Fig. 6) . This approach was possible because wild-type CPD does not contain disulfide bridges. Notably, introduction of a disulfide bond between helix α4 and strand G 3 of the β-flap (I762C E766C) produced a mutant that was more responsive to InsP 6 than wild-type CPD (Fig. 6) . Reduction of this disulfide bond restored wild-type levels of activity to I762C E766C. We observed a similar redox-responsive effect when we engineered a disulfide bond in the upper β-flap region (L755C W761C; Fig. 6) . Furthermore, the L755C-W761C disulfide bond partially complemented the intrinsic defect of the W761C mutant (Fig. 6) , indicating that stabilization of this region can partially overcome the loss of the Arg745-Trp761 interaction. However, disulfide mutants in the lower portion of the β-flap region had the opposite effect on protease activity (Fig. 6) .
Replacement of the Arg745-Glu753 salt bridge with a disulfide bond decreased CPD activity by a factor of ~80 relative to wild type, whereas reduction of the disulfide bond restored activity close to wild-type levels (Fig. 6) . Formation of a disulfide bond across the InsP 6 -binding site (R751C E765C) also severely hampered CPD function, whereas addition of reductant largely reversed this defect (Fig. 6) . These studies suggest that restraining the mobility of the upper β-flap region enhances the responsiveness of the protease to InsP 6 , whereas restraining the mobility in the lower portion strongly diminishes its responsiveness to InsP 6 .
DISCUSSION
Communication between functional sites, or allostery, is central to the regulation of many proteins. In most cases, however, the pathways through which the signal travels are poorly characterized [2] [3] [4] . Here we show that activation of a C. difficile CPD by its allosteric ligand InsP 6 depends on formation of an orchestrated series of interactions within the β-flap. Our results suggest that the β-flap structure functionally and mechanically couples InsP 6 binding to protease activation. Furthermore, our data indicate that, whereas InsP 6 binding rapidly accelerates the formation of this activated conformation, the apoenzyme can transiently, but detectably, sample the activated conformer.
Using systematic mutational and structural analyses, we identified a conserved set of interconnected residues in the β-flap region that directly communicate the InsP 6 signal to the active site. In addition to the InsP 6 interacting residues, which are necessary to sense the InsP 6 signal (Fig. 4c) , this contiguous network involves hydrogen bonding between the InsP 6 interacting residue Arg751 and β-flap residues Asn747 and Glu753; a salt bridge between Glu753 and Arg745; and a π-cation interaction between Arg745 and Trp761. Disrupting the interconnectivity of these interactions reduces protease function, as evidenced by the defect caused by reversing the orientation of the Arg745-Glu753 salt bridge (Fig. 4c) . The allosteric conduit seems to terminate at Trp761, because mutation of Leu755, a residue within van der Waals bond distance, had essentially no effect on CPD activity (Fig. 6) .
Through these mutational analyses, we have identified 12 of 253 CPD residues that participate in InsP 6 signaling (Fig. 4c) . Although additional residues may be involved, perhaps in the substrate-binding region, our data are consistent with the view that a small subset of conserved, physically connected residues propagate allosteric signals between distinct functional sites, as has been recently shown for caspase-1 (ref. 36 ) and FecA 37 . Our finding that ~5% of CPD residues participate in this long-range communication is also consistent with other bioinformatic analyses aimed at identifying allosteric circuits in other proteins using coevolution 38 .
The tryptophan fluorescence assays indicate that InsP 6 signal transduction through this interconnected network of residues leads to movement of the conserved β-flap residue Trp761 into a less solventexposed environment (Fig. 5) . When coupled to activity assays, these biophysical analyses show that InsP 6 -induced structural changes correlate with enzyme activation (Fig. 4c) . The disulfide trapping studies further demonstrate that exogenous stabilization of the upper β-flap structure increases the responsiveness of the CPD to InsP 6 in a r t i c l e s a redox-sensitive manner (Fig. 6) . Collectively, our results support a model in which the active conformation of TcdB CPD is stabilized by β-flap formation. More broadly, these types of analyses provide a framework for determining how structural alterations in an allosteric circuit couple to changes in protein function. The emerging view of allostery proposes that allosteric effectors cause a redistribution in the relative populations of protein conformers rather than formation of a de novo conformer [2] [3] [4] . Thus, allosteric effectors perturb a pre-existing conformational equilibrium 2,39 . Our activity-based probe labeling experiments provide direct evidence in support of this theory. Because the probe is covalent and activity dependent, we could sensitively detect the transient adoption of an active conformer by the apoenzyme over time (Fig. 2) . Our results indicate that probe labeling can be used to dynamically measure protein activation and to detect minor levels of conformers in a given population. We anticipate that activity-based probes 26 will be useful tools for biochemically dissecting allosteric mechanisms of regulation for several enzyme classes.
The adoption of the activated conformer of the CPD upon InsP 6 binding was directly correlated with a reduction in its conformational mobility 5 (Fig. 3) . Furthermore, substrate recognition of a peptide AOMK inhibitor in the presence of InsP 6 more severely restrained the conformational dynamics of the CPD. Inhibitor binding and covalent modification of the InsP 6 -bound TcdB CPD led to a protein that was highly resistant to trypsin digestion and did not release its associated InsP 6 in the transfer assay (Fig. 3) . Notably, we did not observe a similar stabilization of the CPD when we modified the active cysteine with the general alkylating agent NEM. Thus, recognition of an optimal peptide substrate, rather than simple covalent inhibition alone, seems to be the primary factor in restraining CPD dynamics in the presence of InsP 6 (Fig. 3) . We propose that, similar to the activity of caspases 34 , binding of the critical leucine acts as a 'key' that 'locks' the enzyme in a catalytically competent conformation. In contrast with the caspases, however, substrate binding does not induce conformational changes in TcdB CPD 13, 34, 40 . Instead, InsP 6 binding seems to be the driving force behind the structural rearrangements that lead to protease activation, while substrate binding holds the activated conformer in place.
The observation that TcdB CPD remains conformationally flexible in the presence of InsP 6 seems critical to its function as a protease. When the lower β-flap region was constrained by disulfide bond formation, protease activity was strongly diminished; in contrast, reduction of the disulfide bonds restored activity to levels similar to wild type (Fig. 6) . This latter observation indicates that, although the double cysteine mutations disrupted the allosteric circuit, the physical linkage of cysteine residues was primarily responsible for severely reducing protease function. Notably, although the disulfide bond mutants constructed in this study were originally designed to increase the responsiveness of the CPD to InsP 6 , the majority of engineered disulfide linkages decreased TcdB CPD activity. Only the mutants whose disulfide bonds were engineered near the β-flap (but outside the allosteric conduit defined by this study) led to greater responsiveness to InsP 6 (Fig. 6) . For example, the I762C E766C mutant was predicted to stabilize the interaction between helix α4 and strand G 3 of the β-flap, which in TcdA is linked by a salt bridge 15 . Covalent linkage of these residues, which are dispensable for protease activity, increased the sensitivity of TcdB CPD to InsP 6 . We are tempted to speculate that stabilizing the interaction between helix α4 and strand G 3 promotes formation of the β-flap in the presence of InsP 6 . Future structural analyses of the I762C E766C could test this hypothesis.
We observed a similar increase in InsP 6 responsiveness upon formation of a disulfide bond between W761C and the neighboring L755C relative to the reduced form. In contrast, covalent linkage of W761C to R745C effectively ablated enzyme activity (Fig. 6) . Given that Leu755 does not participate in the allosteric conduit (Fig. 5b) , but that Arg745 is a key constituent, these results suggest that restraining protein dynamics within the allosteric circuit may impede signal propagation. Although we cannot discount the possibility that the engineered disulfide bonds alter the overall conformation of the β-flap in addition to 'rigidifying' this region, this interpretation is consistent with the theory that conformational mobility underlies both allostery and catalysis 3, [41] [42] [43] .
On the basis of these observations, restraining the conformational dynamics of TcdB CPD seems to be an effective strategy for preventing the activation of C. difficile glucosylating toxin function by the CPD 44 . Inhibitors that prevent the allosteric transition 45 or that shift the conformational equilibrium to an inactive conformer 46, 47 could be more effective and suitable for therapeutic applications than peptidic compounds that target the active site. A clearer understanding of the activation mechanism might also facilitate the identification of cell-impermeable compounds that prematurely activate the protease and thus prevent the cytotoxic activity domain from entering cells. Such approaches will require studies of CPD dynamics in the context of full-length toxin before and after intoxication, because the holotoxin undergoes marked structural alterations during translocation 48, 49 . Indeed, a major challenge in understanding the allosteric mechanism that governs the autoproteolytic regulation of C. difficile toxin function will be defining how the conformational dynamics of the full-length toxin affects CPD dynamics and function. These studies may further inform our understanding of how InsP 6 modulates protein behavior in a more general sense, because this small molecule directly binds to unrelated bacterial effector proteins 50 and eukaryotic enzymes involved in diverse processes [51] [52] [53] . 
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ONLINE METHODS
Bacterial growth conditions and strain construction. Bacterial strains were grown at 37 °C in Luria-Bertrani (LB) broth. Antibiotics were used at 100 µg ml −1 carbenicillin for pET22b and 30 µg ml −1 kanamycin for pET28a vectors in E. coli. For details on strain construction, see Supplementary Methods and Supplementary Tables 1 and 2.
TcdB CPD AWP19 probe labeling assay. TcdB CPD (residues 544-797) was diluted into CPD buffer (60 mM NaCl, 20 mM Tris, pH 7.5, 250 mM sucrose) to a final concentration of 1 µM. AWP19 was added to a final concentration of 10 µM (1:100 dilution of a DMSO stock) and then 50 µl aliquots were plated in a 96-well plate. InsP 6 (Calbiochem) was added (1:100 dilution from stock in water) to the indicated concentrations in triplicate. AWP19 labeling was allowed to proceed for 1 h at 37 °C after which 30 µl of the reaction was transferred into 10 µl 4× final sample buffer (FSB) in a second 96-well plate. The reaction was boiled for 3 min at 95 °C, and then 10 µl was resolved by SDS-PAGE (14% gel). The gel was scanned using a Typhoon imager and then stained with Coomassie blue to ensure equal loading. For the redox sensitivity assays, the AWP19 probe labeling assay was carried out as described except that the master mix was divided into two, and DTT was added to a final concentration of 1 mM. EC 50 determination. Labeling reactions were quantified in triplicate using the program ImageJ (http://imagej.nih.gov/ij, NIH). The absolute value for each InsP 6 concentration was averaged and then corrected by subtracting the average value at 0 µM InsP 6 . The corrected values were plotted against InsP 6 concentration, and the EC 50 was determined using the Michaelis-Menten function on KaleidaGraph (Synergy Software). Limited chymotrypsin proteolysis. TcdB CPD was diluted into 1.0 ml CPD buffer to a final concentration of 100 µM. The mastermix was divided into three tubes of 300 µl. Ac-GSL-AOMK was added to one tube to a final concentration of 200 µM (20 mM stock in DMSO), while NEM was added to a second tube to a final concentration of 200 µM (50 mM stock in DMSO). The third tube was left untreated. The samples were incubated for 16 h at room temperature after which they were diluted with 900 µl of low-imidazole lysis buffer. Ni-NTA beads (50 µl) were added and incubated with nutation for 1 h at room temperature; immobilized His 6 -tagged TcdB CPD was washed times and then eluted with two times with 100 µl high-imidazole buffer. The TcdB CPD variants were then diluted to 18 µM in 10 mM Tris buffer, pH 7.5, in a total volume of 300 µl. The mixture was split into two, and 1.75 µl of 10 mM InsP 6 was added to one tube for a final concentration of 100 µM. Master mix (24 µl) was aliquoted into a 96-well plate and then chymotrypsin was added to the indicated concentration (1:25 dilution). Limited proteolysis was allowed to proceed for 12 min, after which 7.5 µl of 4× FSB was added to the reactions. The samples were boiled for 3 min at 95 °C, and then 10 µl was resolved on a 14% SDS-PAGE gel and visualized by Coomassie blue staining. Crystallization and data collection. For TcdB CPD bound to InsP 6 , initial crystal hits were observed in 0.1 M Tris HCl, pH 8.0, and 30% (w/v) PEG2000 monomethyl ether as the precipitant. Ultimately, diffraction quality crystals were grown using the sitting-drop vapor-diffusion method by mixing 0.5 µl of protein with an equal volume of mother liquor and allowing the crystals to grow for 45-60 d. Crystals were cryoprotected in 45% (w/v) PEG2000 MME, and data was collected under cryocooled conditions at 100 K at the Advanced Light Source beamline 8.2.1 (Berkeley, California, USA). Diffraction data were processed using MOSFLM 54 and SCALA 55 from the CCP4 suite, and data processing statistics are listed in Table 1 . Electron density of the structure is shown in Supplementary Figure 6 .
Structure determination and refinement. Initial phases were obtained by molecular replacement with PHASER 56 using the structure of the inhibitor-TcdB complex (PDB 3PA8) 25 as a search model. The structure then underwent rounds of restrained refinement with PHENIX 57 followed by model adjustment with COOT 58 , leading to final R and R free values of 19.1% and 24.0%, respectively. Ramachandran analysis of structure geometry with Molprobity indicates 98.1% of residues reside in the most favorable regions, with none in disallowed regions 59 . Refinement statistics are listed in Table 1 . Structural figures were prepared with PyMOL 60 using chain A in all instances. The final model contains two copies of the TcdB CPD in the asymmetric unit, each bound to one molecule of InsP 6 , and a single calcium ion bridging the crystal interface between the two CPD molecules in the asymmetrical unit.
Intrinsic tryptophan fluorescence assay. TcdB CPD variants were diluted to 20 µM in 4.3 ml PBS and divided into 600 µl aliquots. InsP 6 was added to the indicated concentration (100-fold dilution), and then 190 µl aliquots were added in triplicate to a 96-well clear-bottom black plate. The samples were excited at 295 nm, and the emission spectrum was measured at 1 nm increments from 325 nm to 375 nm. InsP 6 was also added to PBS as the buffer control. The A 280 of the plate was measured, and the average A 280 for each prep was determined. The fluorescence values at each wavelength were averaged and the PBS background was subtracted. The resulting RFU value was then divided by the average A 280 value.
